|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Impairment charge on investment in equity securities | |||||
| Interest income | |||||
| Other expense, net | |||||
| Loss before income taxes | |||||
| Income taxes benefit | |||||
| Net loss | |||||
| Net loss per share of common stock - basic (in dollars per share) | |||||
| Net loss per share of common stock - diluted (in dollars per share) | |||||
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | |||||
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | |||||
Loading...